- Home
- MBRX
as 10-17-2024 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 6.6M | IPO Year: | 2016 |
| Target Price: | $35.00 | AVG Volume (30 days): | 47.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $6.24 | Next Earning Date: | 11-11-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
PR Newswire
14 hours ago
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available
GuruFocus.com
8 days ago
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
PR Newswire
11 days ago
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024
PR Newswire
14 days ago
Moleculin to Present at Two Upcoming Investor Conferences
PR Newswire
25 days ago
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
PR Newswire
a month ago
Moleculin Participates in Virtual Investor "What this Means" Segment
PR Newswire
a month ago
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
PR Newswire
a month ago
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.